MA43135A - Compositions et méthodes pour le du traitement du cancer - Google Patents
Compositions et méthodes pour le du traitement du cancerInfo
- Publication number
- MA43135A MA43135A MA043135A MA43135A MA43135A MA 43135 A MA43135 A MA 43135A MA 043135 A MA043135 A MA 043135A MA 43135 A MA43135 A MA 43135A MA 43135 A MA43135 A MA 43135A
- Authority
- MA
- Morocco
- Prior art keywords
- cancer
- compositions
- treatment
- methods
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562249144P | 2015-10-30 | 2015-10-30 | |
US201662331010P | 2016-05-03 | 2016-05-03 | |
US201662396783P | 2016-09-19 | 2016-09-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA43135A true MA43135A (fr) | 2018-09-05 |
Family
ID=58631181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA043135A MA43135A (fr) | 2015-10-30 | 2016-10-28 | Compositions et méthodes pour le du traitement du cancer |
Country Status (13)
Country | Link |
---|---|
US (3) | US10508143B1 (fr) |
EP (1) | EP3368559A4 (fr) |
JP (1) | JP7115982B2 (fr) |
KR (1) | KR20180081532A (fr) |
CN (1) | CN108602872A (fr) |
AU (1) | AU2016343809B2 (fr) |
BR (1) | BR112018008326A2 (fr) |
CA (1) | CA3002674A1 (fr) |
CL (1) | CL2018001152A1 (fr) |
IL (1) | IL258955A (fr) |
MA (1) | MA43135A (fr) |
MX (1) | MX2018005315A (fr) |
WO (1) | WO2017075537A1 (fr) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016343805A1 (en) * | 2015-10-30 | 2018-06-07 | Aleta Biotherapeutics Inc. | Compositions and methods for tumor transduction |
US10508143B1 (en) | 2015-10-30 | 2019-12-17 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
US11020429B2 (en) * | 2015-11-05 | 2021-06-01 | Juno Therapeutics, Inc. | Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy |
JP2019533676A (ja) | 2016-10-13 | 2019-11-21 | ジュノー セラピューティクス インコーポレイテッド | トリプトファン代謝経路調節剤を含む免疫療法の方法および組成物 |
CN108395482B (zh) * | 2017-02-08 | 2021-02-05 | 西比曼生物科技(香港)有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
BR112019017403A2 (pt) * | 2017-02-22 | 2020-04-14 | Aleta Biotherapeutics Inc | composições e métodos para o tratamento de câncer |
US11344578B2 (en) | 2017-04-19 | 2022-05-31 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
EP3621981A2 (fr) | 2017-05-12 | 2020-03-18 | CRISPR Therapeutics AG | Matériaux et procédés de génie cellulaire et leurs utilisations en immuno-oncologie |
CN107177632B (zh) * | 2017-05-27 | 2020-02-07 | 上海优卡迪生物医药科技有限公司 | 一种基于octs技术的髓系白血病car-t治疗载体及其构建方法和应用 |
WO2018232372A1 (fr) * | 2017-06-16 | 2018-12-20 | Protelica, Inc. | Récepteurs d'antigène chimériques à domaine de liaison de la fibronectine et leurs méthodes d'utilisation |
WO2018233624A1 (fr) * | 2017-06-20 | 2018-12-27 | 和迈生物科技有限公司 | Nanocorps anti-her2, séquence de codage et utilisation associée |
SG11202000145XA (en) * | 2017-07-12 | 2020-02-27 | Refuge Biotechnologies Inc | Methods and systems for conditionally regulating gene expression |
US20210130775A1 (en) * | 2017-08-02 | 2021-05-06 | Autolus Limited | Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed |
US20200384022A1 (en) * | 2017-11-13 | 2020-12-10 | The Broad Institute, Inc. | Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas |
CN111655270A (zh) * | 2017-11-14 | 2020-09-11 | 纪念斯隆-凯特琳癌症中心 | 分泌il-36的免疫应答细胞及其用途 |
MA51154A (fr) * | 2017-12-15 | 2020-10-21 | Aleta Biotherapeutics Inc | Variants de cd19 |
CN109988242A (zh) * | 2018-01-02 | 2019-07-09 | 武汉波睿达生物科技有限公司 | 联合嵌合抗原受体、表达载体、慢病毒及t细胞 |
WO2019134526A1 (fr) * | 2018-01-03 | 2019-07-11 | 西交利物浦大学 | Protéine inhibitrice de métalloprotéase de type membranaire, produit pharmaceutique, composition pharmaceutique la contenant et utilisations respectives de celle-ci |
WO2020113403A1 (fr) * | 2018-12-04 | 2020-06-11 | Beijing Percans Oncology Co. Ltd. | Protéines de fusion de cytokines |
CN110157675B (zh) * | 2018-02-12 | 2022-05-27 | 深圳宾德生物技术有限公司 | 一种靶向性t淋巴细胞及其制备方法和应用 |
EP3561053A1 (fr) * | 2018-04-26 | 2019-10-30 | Baylor College of Medicine | Cellules effectrices immunes et adaptateurs moléculaires avec un complexe antigène cytokine pour immunothérapie anticancéreuse efficace |
WO2019210280A1 (fr) * | 2018-04-27 | 2019-10-31 | Casebia Therapeutics Limited Liability Partnership | Cellules car-t anti-bcma pour déplétion de cellules plasmatiques |
EP3784256A4 (fr) * | 2018-04-27 | 2022-06-29 | Baylor College of Medicine | Lymphocytes t car comprenant une ou plusieurs interleukines |
MX2020012028A (es) | 2018-05-11 | 2021-03-29 | Crispr Therapeutics Ag | Metodos y composiciones para tratar el cancer. |
CN110623977A (zh) * | 2018-06-25 | 2019-12-31 | 深圳宾德生物技术有限公司 | 靶向bcma的嵌合抗原受体t细胞在自身免疫性疾病中的应用 |
CN110856751A (zh) | 2018-08-24 | 2020-03-03 | 合成免疫股份有限公司 | 包含核酸及tcr修饰的免疫细胞的治疗剂及其应用 |
CN110950954B (zh) * | 2018-09-26 | 2021-06-25 | 重庆精准生物技术有限公司 | 抗cd123人源化单链抗体及其应用 |
WO2020077341A1 (fr) | 2018-10-13 | 2020-04-16 | Memorial Sloan-Kettering Center Center | Méthodes et compositions pour détecter et traiter les sujets susceptibles de répondre négativement à la thérapie par lymphocytes t à récepteur antigénique chimérique |
AU2019384145A1 (en) * | 2018-11-20 | 2021-06-10 | Innovative Cellular Therapeutics Holdings, Ltd. | Modified cell expressing therapeutic agent and uses thereof |
US20220047634A1 (en) * | 2018-11-30 | 2022-02-17 | Dana-Farber Cancer Institute, Inc. | Chimeric antigen receptor factories and methods of use thereof |
CN109468283A (zh) * | 2018-11-30 | 2019-03-15 | 北京美康基免生物科技有限公司 | 一种基于cd19和bcma的双重嵌合抗原受体基因修饰的免疫细胞及其应用 |
CN109536444B (zh) * | 2018-12-11 | 2022-06-28 | 吉林省拓华生物科技有限公司 | 一种适用于恶性实体瘤肿瘤浸润t淋巴细胞的分离诱导方法 |
CN113677703A (zh) * | 2018-12-17 | 2021-11-19 | 鳄鱼生物科学公司 | 多肽 |
CN111378046B (zh) * | 2018-12-27 | 2024-03-15 | 上海细胞治疗集团有限公司 | 一种免疫效应细胞转换受体 |
CN111378623B (zh) * | 2018-12-29 | 2023-10-20 | 深圳市第三人民医院 | 一种靶向性抗肿瘤t细胞及其制备方法和应用 |
AU2020224160A1 (en) * | 2019-02-21 | 2021-08-26 | John M. LUK | Artificial immunosurveillance chimeric antigen receptor (AI-CAR) and cells expressing the same |
WO2020172641A1 (fr) * | 2019-02-21 | 2020-08-27 | Arbele Limited | Récepteur antigénique chimérique d'immunosurveillance artificielle et cellules l'exprimant |
EP3931212A1 (fr) | 2019-03-01 | 2022-01-05 | Universität für Bodenkultur Wien | Domaine extracellulaire stabilisé de cd19 |
CA3137962A1 (fr) * | 2019-04-26 | 2020-10-29 | Aleta Biotherapeutics Inc. | Compositions et procedes de traitement du cancer |
CA3138633A1 (fr) | 2019-04-30 | 2020-11-05 | Crispr Therapeutics Ag | Therapie cellulaire allogenique de malignites de lymphocytes b a l'aide de lymphocytes t genetiquement modifies ciblant cd19 |
AU2020296197A1 (en) * | 2019-06-21 | 2022-01-20 | Shattuck Labs, Inc. | Chimeric protein expressing T-cells |
KR20220036941A (ko) * | 2019-06-21 | 2022-03-23 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 암 및 기타 질환의 치료를 위한 알파3베타1 인테그린 표적화 |
BR112022003735A2 (pt) * | 2019-08-29 | 2022-06-21 | Nat Institute For Biotechnology In The Negev Ltd | Anticorpo de domínio único para alvejar antígeno de membrana específico da próstata (psma) |
CN114502723A (zh) * | 2019-09-26 | 2022-05-13 | 原启生物科技(上海)有限责任公司 | 一种经修饰的免疫细胞及其用途 |
WO2021096275A1 (fr) * | 2019-11-15 | 2021-05-20 | 주식회사 제넥신 | Protéine de fusion comprenant l'interleukine -7 modifiée et le récepteur bêta ii du tgf et son utilisation |
CN114945586A (zh) * | 2020-01-21 | 2022-08-26 | 张晋宇 | 一种药物组合物及其用途 |
CN115701999A (zh) * | 2020-07-09 | 2023-02-14 | 南京传奇生物科技有限公司 | 用白介素-36工程化γδT细胞用于免疫疗法 |
US20230272341A1 (en) * | 2020-08-10 | 2023-08-31 | Crage Medical Co., Limited | Multifunctional immune effector cell and use thereof |
CN111944063A (zh) * | 2020-08-20 | 2020-11-17 | 深圳市因诺转化医学研究院 | 特异性识别人cd19嵌合抗原受体的融合蛋白、核酸分子及其应用 |
WO2022049217A1 (fr) | 2020-09-04 | 2022-03-10 | Miltenyi Biotec B.V. & Co. KG | Système pour l'expression inductible d'un adaptateur dans des cellules immunitaires |
JP2023541455A (ja) | 2020-09-14 | 2023-10-02 | ブイオーアール バイオファーマ インコーポレーテッド | Cd33に対する単一ドメイン抗体 |
CA3196402A1 (fr) * | 2020-10-22 | 2022-04-28 | Dale L. Ludwig | Combinaison de radioimmunotherapie et de blocage de cd47 dans le traitement du cancer |
CN112225822B (zh) * | 2020-12-14 | 2021-03-23 | 北京基因启明生物科技有限公司 | 高扩增、存续能力和杀瘤作用的CAR-iNKT及应用 |
CN114163512A (zh) * | 2021-03-24 | 2022-03-11 | 深圳市新靶向生物科技有限公司 | 一种与肝癌驱动基因突变相关的抗原肽组合及其应用 |
WO2022246041A2 (fr) * | 2021-05-20 | 2022-11-24 | Achelois Biopharma, Inc. | Compositions et procédés pour un affichage de surface multivalent sur des particules enveloppées |
CN113238061B (zh) * | 2021-07-09 | 2021-10-01 | 中南大学湘雅医院 | 以cd180阴性b细胞指示重症肌无力病情的试剂盒及应用 |
CN116338196A (zh) * | 2021-12-15 | 2023-06-27 | 上海佳文英莉生物技术有限公司 | 老年痴呆症诊断及治疗的新靶点及其应用 |
KR20230101284A (ko) * | 2021-12-29 | 2023-07-06 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 대장암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
KR20230101285A (ko) * | 2021-12-29 | 2023-07-06 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 유방암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
KR20230101287A (ko) * | 2021-12-29 | 2023-07-06 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 흑색종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
KR20230101283A (ko) * | 2021-12-29 | 2023-07-06 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 폐 유두상 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
KR20230101286A (ko) * | 2021-12-29 | 2023-07-06 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 폐 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
WO2023201238A1 (fr) | 2022-04-11 | 2023-10-19 | Vor Biopharma Inc. | Agents de liaison et leurs méthodes d'utilisation |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
US5614191A (en) | 1995-03-15 | 1997-03-25 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
WO1998002548A2 (fr) | 1996-07-17 | 1998-01-22 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Particules pseudovirales de papillomavirus infectieux |
GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
WO1998055607A2 (fr) | 1997-06-04 | 1998-12-10 | Oxford Biomedica (Uk) Limited | Vecteur |
WO1999013056A1 (fr) | 1997-09-05 | 1999-03-18 | Medimmune, Inc. | Methode de desassemblage-reassemblage in vitro de particules viroides (vlp) du papillomavirus |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
AU1086501A (en) | 1999-10-15 | 2001-04-30 | Carnegie Institution Of Washington | Rna interference pathway genes as tools for targeted genetic interference |
US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
WO2001096584A2 (fr) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Matieres et procedes de lutte contre les nematodes |
AU6541801A (en) | 2000-06-22 | 2002-01-02 | Idec Pharma Corp | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
EP1334188B1 (fr) | 2000-11-07 | 2006-08-30 | City of Hope | Cellules immunitaires specifiques a cd19 redirigees |
CN1114690C (zh) | 2001-05-15 | 2003-07-16 | 乔良 | 乳头瘤假病毒及其制备方法 |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
AU2006218489B2 (en) | 2005-03-02 | 2011-02-24 | Biogen Ma Inc. | KIM-1 antibodies for treatment of Th2-mediated conditions |
EP1909832A4 (fr) | 2005-06-29 | 2010-01-13 | Univ Miami | Proteine de fusion anticorps-ligand de cellule immunitaire pour le traitement du cancer |
DK2009990T3 (en) | 2006-04-07 | 2017-01-09 | Univ Texas | METHODS AND COMPOSITIONS RELATED TO adenoassociated VIRUSFAGPARTIKLER |
CA2686990C (fr) | 2007-05-08 | 2018-04-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pseudovirus de papillomavirus pour detection et therapie de tumeurs |
CA2695385A1 (fr) * | 2007-07-31 | 2009-02-05 | Atul Bedi | Conjugue d'acide nucleique de polypeptide destine a l'immunoprophylaxie ou a l'immunotherapie des troubles neoplasiques ou infectieux |
JP6035009B2 (ja) | 2007-08-22 | 2016-11-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
WO2009117117A1 (fr) * | 2008-03-19 | 2009-09-24 | Altor Bioscience Corporation | Protéines hybrides et conjugués de récepteurs de lymphocytes t et procédés d'utilisation de ceux-ci |
AU2009288289B2 (en) | 2008-08-25 | 2012-11-08 | Amplimmune, Inc. | PD-1 antagonists and methods of use thereof |
CA2742777A1 (fr) * | 2008-11-06 | 2010-05-14 | University Of Guelph | Procedes d'amelioration de l'efficacite therapeutique et utilisation de fragments d'anticorps |
JP5851842B2 (ja) | 2009-01-12 | 2016-02-03 | サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. | 改変した抗体組成物、それを作製および使用する方法 |
WO2010096838A2 (fr) | 2009-02-23 | 2010-08-26 | Cytomx Therapeutics, Llc | Proprotéines et leurs procédés d'utilisation |
US20130209514A1 (en) * | 2009-06-09 | 2013-08-15 | Eli Gilboa | Aptamer-targeted costimulatory ligand aptamer |
CA3083324A1 (fr) * | 2010-03-05 | 2011-09-09 | The Johns Hopkins University | Compositions et procedes pour des anticorps et proteines de fusion immunomodulateurs cibles |
EP2632482A4 (fr) * | 2010-10-27 | 2015-05-27 | Baylor College Medicine | Récepteurs cd27 chimères utilisés pour rediriger des lymphocytes t vers des tumeurs malignes positives pour cd70 |
AU2012314860B2 (en) | 2011-09-26 | 2017-02-23 | Philogen S.P.A. | Immunocytokine combination therapy |
GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
IN2014MN02164A (fr) | 2012-04-27 | 2015-08-28 | Cytomx Therapeutics Inc | |
KR20150037857A (ko) | 2012-06-22 | 2015-04-08 | 싸이톰스 테라퓨틱스, 인크. | 항-jagged 1/jagged 2 교차-반응성 항체, 활성화가능한 항-jagged 항체 및 이의 제조 방법 |
US9487590B2 (en) | 2012-09-25 | 2016-11-08 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind interleukin-6 receptor and methods of use thereof |
WO2014055657A1 (fr) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Utilisation d'une approche trans-signalisation dans des récepteurs d'antigènes chimériques |
CN109897100A (zh) * | 2013-05-13 | 2019-06-18 | 瑟勒提斯公司 | Cd19特异性嵌合抗原受体及其用途 |
SG11201600167SA (en) | 2013-07-19 | 2016-02-26 | Vib Vzw | Targeted modified il-1 family members |
JP6734774B2 (ja) * | 2013-10-15 | 2020-08-05 | ザ スクリプス リサーチ インスティテュート | ペプチドキメラ抗原受容体t細胞スイッチおよびその使用 |
KR20230007559A (ko) * | 2013-12-20 | 2023-01-12 | 프레드 허친슨 캔서 센터 | 태그된 키메라 이펙터 분자 및 그의 리셉터 |
EP3811970A1 (fr) | 2014-03-15 | 2021-04-28 | Novartis AG | Récepteur d'antigène chimérique régulable |
ES2939760T3 (es) | 2014-03-15 | 2023-04-26 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico para antígenos |
ES2842212T3 (es) * | 2015-01-26 | 2021-07-13 | Cellectis | Receptores de antígenos quiméricos monocatenarios específicos anti-CLL1 (scCAR) para inmunoterapia contra el cáncer |
EP3283113A4 (fr) * | 2015-04-15 | 2018-12-05 | The California Institute for Biomedical Research | Commutateurs de lymphocytes t à récepteurs d'antigènes chimères à base de pne optimisés et leurs utilisations |
RU2018107754A (ru) * | 2015-08-11 | 2019-09-12 | Селлектис | Клетки для иммунотерапии, созданные для таргетинга антигена cd38 и для инактивации гена cd38 |
AU2016343805A1 (en) | 2015-10-30 | 2018-06-07 | Aleta Biotherapeutics Inc. | Compositions and methods for tumor transduction |
US10508143B1 (en) | 2015-10-30 | 2019-12-17 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
US10259876B2 (en) * | 2016-01-21 | 2019-04-16 | Pfizer Inc. | Chimeric antigen receptors targeting epidermal growth factor receptor variant III |
CA3016555A1 (fr) * | 2016-03-08 | 2017-09-14 | Ventana Medical Systems, Inc. | Immunohistochimie multiplexee utilisant des anticorps recombinants avec des marqueurs d'epitope |
CN109562126A (zh) * | 2016-06-24 | 2019-04-02 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
-
2016
- 2016-10-28 US US15/315,844 patent/US10508143B1/en active Active
- 2016-10-28 JP JP2018543000A patent/JP7115982B2/ja active Active
- 2016-10-28 CA CA3002674A patent/CA3002674A1/fr active Pending
- 2016-10-28 BR BR112018008326-7A patent/BR112018008326A2/pt active Search and Examination
- 2016-10-28 WO PCT/US2016/059582 patent/WO2017075537A1/fr active Application Filing
- 2016-10-28 MA MA043135A patent/MA43135A/fr unknown
- 2016-10-28 KR KR1020187014842A patent/KR20180081532A/ko unknown
- 2016-10-28 EP EP16861008.7A patent/EP3368559A4/fr active Pending
- 2016-10-28 CN CN201680075377.0A patent/CN108602872A/zh active Pending
- 2016-10-28 MX MX2018005315A patent/MX2018005315A/es unknown
- 2016-10-28 AU AU2016343809A patent/AU2016343809B2/en active Active
-
2017
- 2017-12-01 US US15/829,673 patent/US10669349B2/en active Active
-
2018
- 2018-04-26 IL IL258955A patent/IL258955A/en unknown
- 2018-04-30 CL CL2018001152A patent/CL2018001152A1/es unknown
-
2020
- 2020-02-14 US US16/792,118 patent/US11807691B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10669349B2 (en) | 2020-06-02 |
CA3002674A1 (fr) | 2017-05-04 |
BR112018008326A2 (pt) | 2018-10-30 |
US10508143B1 (en) | 2019-12-17 |
MX2018005315A (es) | 2018-08-14 |
US20200255541A1 (en) | 2020-08-13 |
KR20180081532A (ko) | 2018-07-16 |
IL258955A (en) | 2018-06-28 |
JP2019503200A (ja) | 2019-02-07 |
AU2016343809A1 (en) | 2018-05-31 |
EP3368559A1 (fr) | 2018-09-05 |
AU2016343809B2 (en) | 2022-08-04 |
EP3368559A4 (fr) | 2020-01-15 |
CN108602872A (zh) | 2018-09-28 |
CL2018001152A1 (es) | 2018-11-16 |
US11807691B2 (en) | 2023-11-07 |
WO2017075537A1 (fr) | 2017-05-04 |
JP7115982B2 (ja) | 2022-08-09 |
US20180142035A1 (en) | 2018-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA43135A (fr) | Compositions et méthodes pour le du traitement du cancer | |
MA49144A (fr) | Polythérapies pour le traitement du cancer | |
MA43283A (fr) | Procédés et compositions pour le traitement du cancer | |
MA47501A (fr) | Dérivé de di-nucléotides cycliques pour le traitement du cancer | |
MA42420A (fr) | Vaccins pour le traitement et la prévention du cancer | |
MA45563A (fr) | Méthodes de traitement du cancer de l'ovaire | |
MA43746A (fr) | Dérivés de 2-cyanoisoindoline pour le traitement du cancer | |
MA46481A (fr) | Compositions d'oligonucléotides et méthodes associées | |
MA41449A (fr) | Polythérapies pour le traitement de cancers | |
MA41028A (fr) | Méthodes et formulations pour le traitement de pathologies oculaires vasculaires | |
MA45146A (fr) | Dérivés de pyrazolopyridine pour le traitement du cancer | |
MA41119A (fr) | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique | |
MA43374A (fr) | Méthodes de traitement de tumeurs malignes | |
MA41044A (fr) | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer | |
MA46954A (fr) | Méthodes de traitement d'états inflammatoires | |
MA40867A (fr) | Méthodes pour le traitement d'infections virales à filoviridae | |
MA48637A (fr) | Polythérapies pour le traitement du cancer | |
DK3119797T3 (da) | Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose | |
MA50409A (fr) | Polythérapies pour le traitement du cancer | |
MA45429A (fr) | Polythérapie pour le traitement du cancer | |
MA45675A (fr) | Méthodes et compositions permettant le traitement du cancer | |
MA41555A (fr) | Polythérapie pour le traitement du cancer | |
MA41123A (fr) | Polythérapie pour le traitement du cancer | |
MA47408A (fr) | Traitement du cancer | |
MA42999A (fr) | Polythérapie pour le traitement de malignités |